Skip to main content

Danaher Corporation (DHR) Stock Analysis

Falling Knife setup

SellModerate Confidence

Healthcare · Diagnostics & Research

Sell if holding. Momentum 1.2/10 is below the 5.0 floor at $179.58 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: non-U.S. customers (59.0%); Weak growth.

Danaher is a global science and technology company organized in Biotechnology, Life Sciences, and Diagnostics segments, selling products on a recurring basis through a direct sales model to a geographically diverse customer base in approximately 50 countries. In 2025,... Read more

$179.58+25.2% A.UpsideScore 5.0/10#17 of 25 Diagnostics & Research
Stop $169.75Target $225.12(analyst − 10%)A.R:R 4.1:1
Analyst target$250.14+39.3%22 analysts
$225.12our TP
$179.58price
$250.14mean
$310

Sell if holding. Momentum 1.2/10 is below the 5.0 floor at $179.58 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: non-U.S. customers (59.0%); Weak growth. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Score 5.0/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 82d clear, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.

Thesis

Rewards
Strong earnings beat streak (4/4)
Analyst upside: 25%
Risks
Concentration risk — Geographic: non-U.S. customers (59.0%)
Weak growth
Negative momentum

Key Metrics

P/E (TTM)34.6
P/E (Fwd)19.7
Mkt Cap$126.5B
EV/EBITDA17.7
Profit Mgn14.9%
ROE7.1%
Rev Growth3.7%
Beta0.99
Dividend0.89%
Rating analysts30

Quality Signals

Piotroski F9/9

Options Flow

P/C7.92bearish
IV40%normal
Max Pain$130-27.6% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHGeographicnon-U.S. customers59%
    10-K Item 1A: 'In 2025 approximately 59% of our sales from continuing operations were derived from customers outside the U.S.'
  • LOWGeographicChina11%
    10-K Item 1A: 'In 2025 we generated approximately 11% of our sales from continuing operations from China'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
1.5
Rsi
3.5
Volume distribution (falling OBV)Below 200-MA, MA slope flat

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
0.8
Value Rank
2.9
Quality Rank
5.5

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Revenue Growth
3.4
Earnings Growth
4.0
GatesMomentum 1.2<4.5Death cross (50MA < 200MA)A.R:R 4.1 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 82d clearSEMI CYCLE PEAK CLEARFalling KnifeSuitability: Moderate
RSI
38 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $175.00Resistance $200.50

Price Targets

$170
$225
A.Upside+25.4%
A.R:R4.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Momentum score 1.2/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-21 (82d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is DHR stock a buy right now?

Sell if holding. Momentum 1.2/10 is below the 5.0 floor at $179.58 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: non-U.S. customers (59.0%); Weak growth. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Prior stop was $169.75. Score 5.0/10, moderate confidence.

What is the DHR stock price target?

Take-profit target: $225.12 (+25.2% upside). Prior stop was $169.75. Stop-loss: $169.75.

What are the risks of investing in DHR?

Concentration risk — Geographic: non-U.S. customers (59.0%); Weak growth; Negative momentum.

Is DHR overvalued or undervalued?

Danaher Corporation trades at a P/E of 34.6 (forward 19.7). TrendMatrix value score: 6.0/10. Verdict: Sell.

What do analysts say about DHR?

30 analysts cover DHR with a consensus score of 4.2/5. Average price target: $250.

What does Danaher Corporation do?Danaher is a global science and technology company organized in Biotechnology, Life Sciences, and Diagnostics segments,...

Danaher is a global science and technology company organized in Biotechnology, Life Sciences, and Diagnostics segments, selling products on a recurring basis through a direct sales model to a geographically diverse customer base in approximately 50 countries. In 2025, approximately 59% of continuing operations sales were from outside the U.S.; the Danaher Business System guides continuous improvement across more than 15 operating companies.

Related stocks: ILMN (Illumina, Inc.) · IQV (IQVIA Holdings, Inc.) · NTRA (Natera, Inc.) · DGX (Quest Diagnostics Incorporated) · MTD (Mettler-Toledo International, I)